These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 25174628)

  • 1. The economics, financing and implementation of HIV treatment as prevention: what will it take to get there?
    Wilson D; Taaffe J; Fraser-Hurt N; Gorgens M
    Afr J AIDS Res; 2014; 13(2):109-19. PubMed ID: 25174628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economics of antiretroviral treatment vs. circumcision for HIV prevention.
    Bärnighausen T; Bloom DE; Humair S
    Proc Natl Acad Sci U S A; 2012 Dec; 109(52):21271-6. PubMed ID: 23223563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV treatment as prevention: issues in economic evaluation.
    Bärnighausen T; Salomon JA; Sangrujee N
    PLoS Med; 2012; 9(7):e1001263. PubMed ID: 22802743
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Opportunities and Challenges in HIV Treatment as Prevention Research: Results from the ANRS 12249 Cluster-Randomized Trial and Associated Population Cohort.
    Tanser F; Kim HY; Vandormael A; Iwuji C; Bärnighausen T
    Curr HIV/AIDS Rep; 2020 Apr; 17(2):97-108. PubMed ID: 32072468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A scoping study to identify opportunities to advance the ethical implementation and scale-up of HIV treatment as prevention: priorities for empirical research.
    Knight R; Small W; Pakula B; Thomson K; Shoveller J
    BMC Med Ethics; 2014 Jul; 15():54. PubMed ID: 24994501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Implementing universal HIV treatment in a high HIV prevalence and rural South African setting - Field experiences and recommendations of health care providers.
    Plazy M; Perriat D; Gumede D; Boyer S; Pillay D; Dabis F; Seeley J; Orne-Gliemann J
    PLoS One; 2017; 12(11):e0186883. PubMed ID: 29155832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trends and economic stress: a challenge to universal access to antiretroviral treatment in India.
    Dhamija P; Bansal D; Medhi B
    Curr HIV Res; 2009 Jul; 7(4):410-7. PubMed ID: 19601776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Who pays and why? Costs, effectiveness, and feasibility of HIV treatment as prevention.
    Wilson D; Fraser N
    Clin Infect Dis; 2014 Jul; 59 Suppl 1():S28-31. PubMed ID: 24926029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment as Prevention: Concepts and Challenges for Reducing HIV Incidence.
    Brault MA; Spiegelman D; Hargreaves J; Nash D; Vermund SH
    J Acquir Immune Defic Syndr; 2019 Dec; 82 Suppl 2(2):S104-S112. PubMed ID: 31658196
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Costs associated with combination antiretroviral therapy in HIV-infected patients.
    Yazdanpanah Y
    J Antimicrob Chemother; 2004 Apr; 53(4):558-61. PubMed ID: 14985277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Smart cascades: using cost analysis to improve HIV care and treatment interventions to achieve global 95-95-95 goals.
    Cantelmo CB; Lee B; Dutta A
    Afr J AIDS Res; 2019 Dec; 18(4):350-359. PubMed ID: 31779567
    [No Abstract]   [Full Text] [Related]  

  • 12. Human Resources for Treating HIV/AIDS: Are the Preventive Effects of Antiretroviral Treatment a Game Changer?
    Bärnighausen T; Bloom DE; Humair S
    PLoS One; 2016; 11(10):e0163960. PubMed ID: 27716813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Innovative Strategies for Scale up of Effective Combination HIV Prevention Interventions in Sub-Saharan Africa.
    Shanaube K; Bock P
    Curr HIV/AIDS Rep; 2015 Jun; 12(2):231-7. PubMed ID: 25929960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic impact of HIV.
    Veenstra N; Whiteside A
    Best Pract Res Clin Obstet Gynaecol; 2005 Apr; 19(2):197-210. PubMed ID: 15778110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic evaluation of differentiated service delivery models for HIV treatment in Lesotho: costs to providers and patients.
    Nichols BE; Cele R; Lekodeba N; Tukei B; Ngorima-Mabhena N; Tiam A; Maotoe T; Sejana MV; Faturiyele IO; Chasela C; Rosen S; Fatti G
    J Int AIDS Soc; 2021 Apr; 24(4):e25692. PubMed ID: 33838012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effectiveness and cost implications of task-shifting in the delivery of antiretroviral therapy to HIV-infected patients: a systematic review.
    Mdege ND; Chindove S; Ali S
    Health Policy Plan; 2013 May; 28(3):223-36. PubMed ID: 22738755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Cost-effectiveness of initial adherence to antiretroviral therapy among HIV infected patients in Belo Horizonte, Brazil].
    Acurcio Fde A; Puig-Junoy J; Bonolo Pde F; Braga Ceccato Md; Guimarães MD
    Rev Esp Salud Publica; 2006; 80(1):41-54. PubMed ID: 16553259
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The road to success. Long-term prognosis for persons living with HIV in Denmark - time trends and risk factors.
    Lohse N
    Dan Med J; 2016 Feb; 63(2):. PubMed ID: 26836803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Annual cost of antiretroviral therapy among three service delivery models in Uganda.
    Vu L; Waliggo S; Zieman B; Jani N; Buzaalirwa L; Okoboi S; Okal J; Borse NN; Kalibala S
    J Int AIDS Soc; 2016; 19(5 Suppl 4):20840. PubMed ID: 27443270
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.